Eyepoint, Inc. · NASDAQ:EYPT

Eyepoint — EyePoint Pharmaceuticals — Investor Presentation (July 2025)

26 slides from Eyepoint's investor presentation, July 2025

  1. Slide 1: Investor Presentation

    Investor Presentation July 2025 ©2025 EyePoint Pharmaceuticals, Inc. All Rights Reserved.

  2. Slide 2: Legal Disclaimers

    Legal Disclaimers Various statements made in this presentation are forward-looking, within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, and are inherently subject to risks, uncertainties and potentially inaccurate assumptions. All statements that address activities, even

  3. Slide 3: The Leader in Sustained Release Drug Delivery for Retinal Disease

    The Leader in Sustained Release Drug Delivery for Retinal Disease DURAVYU : vorolanib - best-in-class, patent protected TKI in next-generation Durasert E sustained delivery technology LUGANO and LUCIA Phase 3 wet AMD trials fully enrolled >800 patients randomized Compelling efficacy and safety data

  4. Slide 4: Pipeline Leveraging Bioerodible Durasert E Drug Delivery Technology Pursuing Large Market Opportunities

    Pipeline Leveraging Bioerodible Durasert E Drug Delivery Technology Pursuing Large Market Opportunities Anticipated Next Durasert E Programs Indication Discovery Pre-Clin Phase 1 Phase 2 Phase 3 Milestone LUGANO topline data Wet AMD LUGANO and LUCIA fully enrolled expected in mid 2026; DURAVYU – (vo

  5. Slide 5: Many patients with wet AMD are chronically undertreated

    1 Many patients with wet AMD are chronically undertreated >80% of Retina Specialists say undertreatment due to patient noncompliance, scheduling limitations or provider preference for less frequent dosing1 Despite current 2 Chronic disease treated with short acting anti-VEGFs places significant burd

  6. Slide 6: Diabetic Macular Edema: Large Market Opportunity with Significant Unmet Need for More Durable Treatments

    Diabetic Macular Edema: Large Market Opportunity with Significant Unmet Need for More Durable Treatments up to 5-6 54.9M 25% $3.0B 51% letters Patients in the US with Develop DME Global branded Delayed/missed Vision loss from diabetes by 20301 within 10 years2 market by treatment visits4 missed inje

  7. Slide 7: Durasert E: The Next Generation in Sustained-Release Intravitreal Drug Delivery

    Durasert E : The Next Generation in Sustained-Release Intravitreal Drug Delivery Durasert® Durasert E Over three decades of innovation in sustained- release drug delivery Nonerodible EYP-1901 DURAVYU (EYP-1901) ILUVIEN® (vorolanib IVT insert) (vorolanib IVT insert) (fluocinolone Vitrasert® (ganciclo

  8. Slide 8: DURAVYU: Vorolanib in Bioerodible Durasert E

    DURAVYU : Vorolanib in Bioerodible Durasert E DURAVYU Vorolanib: most studied TKI in Durasert E Immediate* retinal disease Bioerodible, sustained No delay - reaches target tissues at therapeutic levels within hours Novel MOA: Selective and potent TKI that IVT drug delivery works intracellularly to i

  9. Slide 9: DURAVYU Demonstrated Robust Efficacy Outcomes and an Excellent Safety Profile Across Multiple Indications

    DURAVYU Demonstrated Robust Efficacy Outcomes and an Excellent Safety Profile Across Multiple Indications DURAVYU HAS BEEN EVALUATED IN >190 PATIENTS TO DATE ACROSS FOUR CLINICAL TRIALS 17 DAVIO • Stable BCVA and OCT patients received DURAVYU Phase 1 Wet AMD • 74% reduction in treatment burden • Sta

  10. Slide 10: LUGANO/LUCIA Phase 3 Pivotal Trials in wet AMD

    Fully Enrolled LUGANO/LUCIA Phase 3 Pivotal Trials in wet AMD NON-INFERIORITY VERSUS ON- LABEL AFLIBERCEPT CONTROL ©2025 EyePoint Pharmaceuticals, Inc. All Rights Reserved.

  11. Slide 11: DURAVYU De-Risked Clinical Approach in Wet AMD

    DURAVYU De-Risked Clinical Approach in Wet AMD ESTABLISHED FDA COMPLETED ROBUST PROACTIVE FDA PATIENT-CENTRIC APPROVAL PATH PHASE 2 TRIAL INTERACTION APPROACH • All patients • Last four FDA • Derisked and • Formal EOP2 and receive treatment approvals followed informed Phase 3 Type C meetings with th

  12. Slide 12: Positive Phase 2 DAVIO 2 Results in Wet AMD Support Ongoing DURAVYU Phase 3

    Positive Phase 2 DAVIO 2 Results in Wet AMD Support Ongoing DURAVYU Phase 3 Pivotal Program ACHIEVED ALL PRIMARY AND SECONDARY ENDPOINTS DAVIO2 Endpoint 2mg 3mg  Primary: Non-inferior change in BCVA vs. - 0.3 letters - 0.4 letters aflibercept  Secondary: Favorable safety profile No DURAVYU-related

  13. Slide 13: Phase 3 Pivotal Trials - Designed to Evaluate Non-Inferiority of DURAVYU vs On-Label Aflibercept

    Phase 3 Pivotal Trials - Designed to Evaluate Non-Inferiority of DURAVYU vs On-Label Aflibercept Control W60- W84- W96 Screening D1 W4 W8 W12 W16 W20 W24 W28 W32 W36 W40 W44 W48 W52 W56 W80 W76 W92 EOS RA NDOMI Z AT IO N DURA VY U DURA VY U DURA VY U DURA VY U DURAVYU 2.7mg Aflibercept 2mg q8W A FL

  14. Slide 14: Exceptional Enrollment in Pivotal Phase 3 Wet AMD Program

    Exceptional Enrollment in Pivotal Phase 3 Wet AMD Program Driven by Strong Enthusiasm for the DURAVYU Pivotal Program January February March 10, May 2, May 2025 July 2025 Mid- 2025 28, 2025 2025 2025 2026 LUGANO trial LUGANO trial LUGANO 60% LUGANO LUGANO LUCIA enrollment enrollment Topline data ~1/

  15. Slide 15: Phase 2 VERONA Clinical Trial in DME

    Phase 2 VERONA Clinical Trial in DME 24 WEEK RESULTS PRIMARY AND SECONDARY ENDPOINTS ACHIEVED ©2025 EyePoint Pharmaceuticals, Inc. All Rights Reserved. DME, diabetic macular edema

  16. Slide 16: DURAVYU is Uniquely Positioned to Provide an Improved DME Treatment Paradigm

    DURAVYU is Uniquely Positioned to Provide an Improved DME Treatment Paradigm Compared to Current Anti-VEGF Therapies 24-Month Treatment Regimens for DME: 2-month dosing 2–4-month dosing 1-month dosing 1-4-month dosing DURAVYU Anti-VEGF (vorolanib SoC intravitreal insert)* 6-month dosing *Potential p

  17. Slide 17: VERONA: DURAVYU demonstrated stability in vision and anatomical control with fewer injections in DME

    DURAVYU 2.7mg EFFICACY: VERONA: • Primary endpoint met - extended time to first supplemental DURAVYU injection vs. aflibercept control demonstrated • Key secondary endpoints met: • Rapid and sustained BCVA improvement = +10.1* letters stability in vision • Rapid and sustained CST improvement = -76 m

  18. Slide 18: DURAVYU 2.7mg Improved +10 Letters vs. Baseline; Nearly +3 Letters Better than Control at 24 Weeks

    DURAVYU 2.7mg* Improved +10 Letters vs. Baseline; Nearly +3 Letters Better than Control at 24 Weeks M EAN CHA NG E I N B CVA F RO M BAS EL I NE Mean Change in BCVA vs Aflibercept 15 DURAVYU 2.7mg* +2.8 Change in ETRDS letters 10 +10.1 +7.3 +6.9 5 0 Randomization Week 4 Week 8 Week 12 Week 16 Week 20

  19. Slide 19: DURAVYU 2.7mg Demonstrated Improved Anatomical Control with 74% More Drying than Aflibercept Control

    DURAVYU 2.7mg Demonstrated Improved Anatomical Control with 74% More Drying than Aflibercept Control M EAN CHA NG E I N C ST F RO M BASE L I NE 20 10 0 CST Change, in microns -10 Mean Change in CST vs Aflibercept -20 DURAVYU 2.7mg -30 -32.2 um -40 -43.7 um -50 -60 -70 -71.1 um -80 -75.9 um -90 -100

  20. Slide 20: Sub-Group of Supplement-Free Patients Demonstrated Better Visual and Anatomical Outcomes

    Sub-Group of Supplement-Free Patients Demonstrated Eyes Treated with DURAVYU 2.7mg had Better Visual and Anatomical Outcomes Mean Change in BCVA vs Aflibercept M EAN CHA NG E I N B CVA F RO M BAS EL I NE DURAVYU 2.7mg 15 +7.3 Change in ETRDS letters 10 +10.3 +6.5 5 +3.0 0 -5 Randomization Week 4 Wee

  21. Slide 21: VERONA Case Study - Rapid Drying with Improved Vision After Single DURAVYU 2.7mg Treatment

    VERONA Case Study 1 - Rapid Drying with Improved Vision After Single DURAVYU 2.7mg Treatment and No Supplementation A FLIB ER CE P T + 2 . 7 m g D UR A VY U Screening Eylea Eylea Vabysmo washout BCVA 50 -12 -11 -10 -9 -8 -7 -6 -5 -4 -3 -2 -1 Day1 1 2 3 4 5 6 Months Case 1: SOC Anti-VEGF Injections B

  22. Slide 22: VERONA Case Study – Better VA and Drying Than Vabysmo After Single DURAVYU 2.7mg Treatment

    VERONA Case Study 2 – Better VA and Drying Than Vabysmo After Single DURAVYU 2.7mg Treatment and No Supplementation A FLIB ER CE P T + 2 . 7 m g D UR AVYU Screening Avastin Vabysmo washout BCVA 72 -12 -11 -10 -9 -8 -7 -6 -5 -4 -3 -2 -1 Day1 1 2 3 4 5 6 Months Case 2: SOC Anti-VEGF Injections Before

  23. Slide 23: VERONA: Phase 2 Clinical Trial Summary

    VERONA: Phase 2 Clinical Trial Summary ✓ Primary endpoint met for both DURAVYU doses ✓ Demonstrated rapid and clinically meaningful results without a full load of aflibercept ✓ Significant improvement in vision and anatomic results paired with a meaningful reduction in treatment burden ✓ Sub-group a

  24. Slide 24: State-Of-The-Art cGMP Manufacturing Facility to Support DURAVYU

    State-Of-The-Art cGMP Manufacturing Facility to Support DURAVYU through Potential NDA Filing and Global Commercial Production ✓ 41,000sf commercial manufacturing ✓ Located in Northbridge, MA ✓ Built to EYPT specifications by landlord preserving upfront cash investment ✓ Built to US FDA and EU EMA st

  25. Slide 25: On Track for Continued Execution And Well-Funded Through Key Anticipated DURAVYU Milestones

    On Track for Continued Execution And Well-Funded Through Key Anticipated DURAVYU Milestones DU RAVYU ✓ Positive interim VERONA data October 2024 ✓ First patient dosed – LUGANO October 2024 ✓ First patient dosed – LUCIA December 2024 ✓ VERONA Phase 2 DME full 24-week data February 2025 ✓ VERONA Phase

  26. Slide 26: Investor Presentation

    Investor Presentation July 2025 ©2025 EyePoint Pharmaceuticals, Inc. All Rights Reserved.

EyePoint Pharmaceuticals — Investor Presentation (July 2025) on 6ix